ArticleTranslational oncology2018

Short-Term Responders of Non-Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms.

Yanjun Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.